CK-0045 is under clinical development by CytoKi Pharma and currently in Phase I for Inflammatory Bowel Disease. According to GlobalData, Phase I drugs for Inflammatory Bowel Disease have a 75% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how CK-0045’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Likelihood of Approval and Phase Transition Success Rate Model - CK-0045 in Inflammatory Bowel Disease

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

CK-0045 overview

CK-0045 is under development for the treatment of epithelial injury in inflammatory bowel disease and obesity. It comprises of an engineered, long-acting lipidated IL-22. It targets interleukin 22 receptor (IL22R) and is being developed based on lipidation technology. It is administered through subcutaneous route.

CytoKi Pharma overview

CytoKi Pharma is a clinical-stage biotechnology company that develops protein drugs for epithelial injury such as inflammatory bowel disease (IBD). The company’s lead drug candidate Interleukin-22 (IL-22) treats a broad range of diseases involving the gut-brain-liver axis such as type-2 diabetes, obesity and non-alcoholic fatty liver disease (NAFLD). Its funding partners include ND Capital, Lundbeck Foundation, Seventure Partners and Ysios Capital Partner. Cytoki Pharma is headquartered in Copenhagen, Denmark.

For a complete picture of CK-0045’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.